drugset / Trial / NCT01380951

Safety and Efficacy of Telbivudine on Liver Cirrhosis in Patients With Chronic Hepatitis B (CHB)

NCT01380951

Phase 4 Unknown 120 enrolled The Fifth People's Hospital of Suzhou
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Antiviral treatment on Chronic Hepatitis B (CHB) patients with liver cirrhosis is compulsory and effective. Telbivudine, which is superior to lamivudine in the treatment of CHB,is considered to be appropriate for the antiviral treatment on CHB patients with liver cirrhosis.

Timeline

Start
2011-05
Primary completion
2012-12
Completion
2013-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Telbivudine Small molecule 600 mg